Vericel Corporation
Financials
Valuation Metrics
Vericel Corporation's Market Cap is $2.04B. At end of 2025 it was $1.82B. Ranked #2017 of 3,121 in US market (top 65%), #769 of 1,463 on NASDAQ (top 53%), #138 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.04B | US#2,017/3,121 Sec#138/266 |
| Revenue | $306M | US#2,454/3,121 Sec#96/266 |
| Net Income | $24M | US#2,075/3,121 Sec#65/266 |
| Total Assets | $503M | US#2,766/3,121 Sec#166/266 |
| Net Assets | $370M | US#2,427/3,121 Sec#143/266 |
| Employees | 398 | US#2,341/3,121 Sec#95/266 |
| Value | ||
| P/E | 84.38x | US#2,068/3,121 Sec#63/266 |
| P/B | 5.52x | US#2,297/3,121 Sec#149/266 |
| PEG | 0.35x | US#486/3,121 Sec#17/266 |
| P/S | 6.67x | US#2,504/3,121 Sec#94/266 |
| EV/EBITDA | 52.29x | US#2,371/3,121 Sec#73/266 |
| FCF Yield | 2.43% | US#1,953/3,121 Sec#64/266 |
| Profitability | ||
| ROE | 6.55% | US#1,724/3,121 Sec#55/266 |
| ROA | 4.82% | US#1,083/3,121 Sec#51/266 |
| Op. Margin | 5.95% | US#1,913/3,121 Sec#70/266 |
| Revenue Growth | 22.95% | US#598/3,121 Sec#71/266 |
| Earnings Growth | 240.80% | US#140/3,121 Sec#9/266 |
| Financial Health | ||
| Debt Ratio | 35.89% | US#407/3,121 Sec#119/266 |
| Total Debt | $93M | US#2,464/3,121 Sec#125/266 |
| FCF | $50M | US#1,995/3,121 Sec#71/266 |
| Cash | $125M | US#2,068/3,121 Sec#152/266 |
| Current Ratio | 5.04x | US#469/3,121 Sec#145/266 |
| Net Debt/EBITDA | -0.85x | US#312/3,121 Sec#22/266 |
| Performance | ||
| 1Y Return | 25.65% | US#834/3,121 Sec#134/266 |
| 1M Return | -8.15% | US#2,396/3,121 Sec#181/266 |
| From 52W High | -18.86% | US#1,428/3,121 Sec#101/266 |
| 1Y MDD | -31.03% | US#1,496/3,121 Sec#93/266 |
| Trading | ||
| Volume | 1,062,489 shares | US#1,973/3,121 Sec#205/266 |
| Trading Value | $42M | US#1,851/3,121 Sec#146/266 |
| Per Share | ||
| EPS | $0.47 | US#1,898/3,121 Sec#59/266 |
| BPS | $7.25 | US#2,066/3,121 Sec#96/266 |
Company Info
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.